Efficacy of intravenous infliximab in axial spondyloarthritis: impact on disease activity, quality of life, and productivity in subgroups with psoriasis and inflammatory bowel disease
This study provides real-world evidence that infliximab improved disease activity, quality of life, and work productivity in all patient groups. Although subgroup differences were not statistically significant, these findings suggest consistent therapeutic benefits across diverse clinical presentations of axSpA.
Authors
- Elpida Skouvaklidou (ORCID: https://orcid.org/0000-0002-0476-154X)
- Maria Boutel
- Dimitrios Deligeorgakis (ORCID: https://orcid.org/0000-0002-1379-4888)
- Paraskevi Avgerou
- N. Kougkas
- Theodoros Dimitroulas (ORCID: https://orcid.org/0000-0002-0364-1642)
- Christina Adamichou (ORCID: https://orcid.org/0000-0001-7374-7795)
- Vasileios Skepastianos (ORCID: https://orcid.org/0009-0009-2368-7064)
- Afroditi Mpitouli
- Konstantinos Tsafis (ORCID: https://orcid.org/0009-0005-3386-597X)
- Vasiliki Dimitriadou
Institutions
- Hippocration General Hospital (GR)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1080/14712598.2026.2617294
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00